We are excited for our portfolio company, Mediar Therapeutics, which reached a new milestone today in dosing their first cohort of participants in their ongoing Ph-1 MTX-463 study.
Mediar is thrilled to share we have initiated our second clinical program in our portfolio of novel first-in-class antibodies designed to halt fibrosis and received both orphan drug and fast track designations for MTX-463, our anti-WISP program in a separate Ph-1 study: two pivotal milestones in our pursuit to fulfill the significant gap in #fibrosis treatment. By targeting the myofibroblast - the key pathogenic cell in fibrosis that drives scarring, disease progression and organ failure - we aim to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. Read more here: https://lnkd.in/gM2pqQEy #Biotech